How Are the Muscles Affected in Cerebral Palsy? A Study of Muscle Biopsies Taken During Orthopaedic Surgery.

Cerebral Palsy Clinical Trial

— CPTDBiopsy  

Official title:

How Are the Muscles Affected in Cerebral Palsy? A Study of Muscle Biopsies Taken During Orthopaedic Surgery of Children With Cerebral Palsy and Typically Developed Children (Control).

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05506228
• Other study ID #: CP muskel OP + kontr
• Status: Recruiting
• Start date: January 15, 2002
• Est. completion date: December 15, 2033

Study information

• Verified date: August 2022
• Source: Region Stockholm
• Contact: Eva M Pontén, MD PhD
• Phone: +46706303052
• Email: eva.ponten[@]ki.se
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

• Cerebral palsy (CP) is a motor disorder caused by an injury to the immature brain. Even though the brain damage does not change, children with CP will have progressively weaker, shorter and stiffer muscles that will lead to contractures, bony deformations, difficulty to walk and impaired manual ability. An acquired brain injury (ABI) later during childhood, such as after a stroke or an injury, will result in similar muscle changes, and will therefore also be included in this study. For simplicity, these participants will in this text be referred to as having CP.

• The mechanism for the muscle changes is still unknown. Contractures and the risk for the hips to even dislocate is now treated by tendon lengthening, muscle release and bony surgery. During these surgeries muscle biopsies, tendon biopsies and blood samples will be taken and compared with samples from typically developed (TD) children being operated for fractures, knee injuries, and deformities. The specimens will be explored regarding inflammatory markers, signaling for muscle growth, signaling for connective tissue growth and muscle and tendon pathology. In blood samples, plasma and serum, e.g. pro-inflammatory cytokines and the cytoprotective polypeptide humanin will measured, and will be correlated to the amount humanin found in muscle. With this compound information the mechanism of contracture formation may be found, and hopefully give ideas for treatment that will protect muscle and joint health, including prevention of hip dislocation and general health.

• The results will be correlated to the degree of contracture of the joint and the severity of the CP (GMFCS I-V, MACS I-V).

• By comparing muscle biopsies from the upper limb with muscle biopsies from the lower limb, muscles that are used in more or less automated gait will be compared to muscles in the upper limb that are used more voluntarily and irregularly.

• Muscles that flex a joint, often contracted, will be compared with extensor muscles from the same patient. Fascia, aponeurosis and tendon will also be sampled when easily attainable.

Description:

• Cerebral palsy (CP) is a motor disorder caused by an injury to the immature brain. Even though the brain damage does not change, children with CP will have progressively weaker, shorter and stiffer muscles that will lead to contractures, bony deformations, difficulty to walk and impaired manual ability. An acquired brain injury (ABI) later during childhood, such as after a stroke or an injury, will result in similar muscle changes, and will therefore also be included in this study. For simplicity, these participants will in this text be referred to as having CP.

• The mechanism for the muscle changes is still unknown. Contractures and the risk for the hips to even dislocate is now treated by tendon lengthening, muscle release and bony surgery. During these surgeries muscle biopsies, tendon biopsies and blood samples will be taken and compared with samples from typically developed (TD) children being operated for fractures, knee injuries, and deformities. The specimens will be explored regarding inflammatory markers, signaling for muscle growth, signaling for connective tissue growth and muscle and tendon pathology. In blood samples, plasma and serum, e.g. pro-inflammatory cytokines and the cytoprotective polypeptide humanin will be measured and correlated to the amount humanin found in muscle. With this compound information the mechanism of contracture formation will hopefully be found and give ideas for treatment that will protect muscle and joint health including prevention of hip dislocation and general health.

• Research questions:

Contracture formation in CP is caused by:

Stiffer muscle/tendon complex? Is there more extracellular matrix around the muscle fiber bundles in CP? Are there pathological intramuscular aponeuroses and tendons? Reduced muscle growth? Are the satellite cells fewer and less active in CP? Is the ribosome number and function affected? Are pro-inflammatory cytokines increased, diminishing growth?

Muscle weakness in CP is caused by impaired metabolic function, caused by:

Fewer mitochondriae? Less mitochondrial ribosomes? Higher percentage of the faster and fatigable myosin MHCIIX? More developmental myosins (neonatal and embryonic myosin)? Decreased PGC-1α?

• Blood samples: Will there be increased expression of pro-inflammatory cytokines, correlating to cytokine expression in muscle and to muscle pathology? Is humanin levels in plasma correlated to muscle levels?

• Muscle samples and tendon samples will be taken during clinically indicated and planned orthopaedic surgery from muscles that are easily exposed from the incisions needed for the primary surgery. Muscle samples 3x3x8 mm from 2-8 different muscles will be taken in such a way that there will be no diminished clinical function. Tendon samples 3x3x3 mm will be taken so that no biomechanical damage occurs. The samples are snap frozen and are stored in -80°C for later analyses. Biopsies are also put fresh in Allprotect (Qiagen) which stabilizes DNA, RNA and proteins, and are kept in a refrigerator for later analyses with e.g. ELISA and PCR.

• The results will be correlated to the degree of contracture of the joint and the severity of the CP (GMFCS I-V, MACS I-V).

• By comparing muscle biopsies from the upper limb with muscle biopsies from the lower limb, muscles that are used in more or less automated gait can be compared to muscles in the upper limb that are used more voluntarily and irregularly.

• Muscles that flex a joint, often contracted, will be compared with extensor muscles from the same patient. Fascia, aponeurosis and tendon will also be sampled when easily attainable.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 15, 2033
• Est. primary completion date: December 15, 2032
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Years to 18 Years

Eligibility

Inclusion Criteria:

• Children and adolescents undergoing clinically needed orthopaedic surgery

• with Cerebral Palsy or Acquired Brain Injury

• Typically developed children and adolescents (control)

Exclusion Criteria:

• for CP/ABI: Progressive neurological disease, other metabolic or muscle disease

• for TD (Control): Cerebral Palsy, Acquired Brain injury, other metabolic or muscle diseases

Related Conditions & MeSH terms

• Cerebral Palsy
• Contracture
• Muscle
• Muscle Contracture
• Muscle Spasticity
• Paralysis

Intervention

Other:
• No intervention

Locations

Country	Name	City	State
Sweden	Karolinska University Hospital	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Eva Ponten

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Muscle/tendon morphology	morphology classification	2002- 2027
Primary	Muscle metabolism	NADH staining classification	2002- 2027
Primary	Fiber area	um 2, square micrometer	2002- 2027
Secondary	Clinical data, Contracture	degrees	Pre-OP